Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.38 |
| ▸ | FAP | Q12884 | 6/20 | 0.35 |
| ▸ | PREP | P48147 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607610 | 0.84 | DPP4 (0.41) | DPP4FAPPREPDPP8DPP9 | |
| SCHEMBL3597277 | 0.84 | DPP4 (0.46) | DPP4PREPDPP8DPP9 | |
| SCHEMBL3597539 | 0.83 | OPRM1 (0.36) | HSD17B10 | |
| SCHEMBL5373165 | 0.74 | DPP4 (0.40) | DPP4FAPPREPDPP8DPP9 | |
| SCHEMBL23760630 | 0.74 | DPP4 (0.52) | DPP4FAPPREPDPP9CTSK | |
| SCHEMBL21105037 | 0.74 | DPP4 (0.52) | DPP4FAPPREPDPP9CTSK | |
| SCHEMBL22169492 | 0.74 | DPP4 (0.52) | DPP4FAPPREPDPP9CTSK | |
| SCHEMBL21105170 | 0.73 | DPP4 (0.50) | DPP4FAPPREPDPP8DPP9 | |
| SCHEMBL17180405 | 0.73 | DPP4 (0.50) | DPP4FAPPREPDPP8DPP9 | |
| SCHEMBL17180404 | 0.73 | DPP4 (0.50) | DPP4FAPPREPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | DPP4 256/4885FAP 1/4885PREP 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.